CXCR4 and neoplasm: In a syngeneic ovarian cancer model, locoregional delivery of the oncolytic vaccinia virus (OVV)-plus CXCR4 antagonist (CXCR4-A) reduced the tumor load and promoted the immune response through CD103 + dendritic cells [45].